Merck (MRK) 1-Year Sharpe Ratio : -3.40 (As of Jul. 01, 2025)

View and export this data going back to 1949. Start your Free Trial

What is Merck 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-01), Merck's 1-Year Sharpe Ratio is -3.40.

Competitive Comparison of Merck's 1-Year Sharpe Ratio

For the Drug Manufacturers - General subindustry, Merck's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck's 1-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Merck's 1-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Merck 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Merck (NYSE:MRK) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Merck 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Merck's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » 1-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRK:Chile MRK:Canada MRCK34:Brazil 6MK:Bulgaria MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Executives

Johannes Jacobus Oosthuizen	officer: SVP, U.S. Market	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
David Michael Williams	officer: EVP,Chief Info&Digital Officer	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Inge G Thulin	director	1250 5TH AVENUE SOUTH, NAPLES FL 34102
Cristal N Downing	officer: Chief Comm. & Public Afrs Ofcr	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Baker Douglas M Jr	director	370 WBASHA ST NORTH, ST PAUL MN 55102
Robert M Davis	officer: Evp, Global Svcs & CFO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Caroline Litchfield	officer: EVP & CFO	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Joseph Romanelli	officer: President, Human Health Int?l	126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Dean Y Li	officer: Executive VP & President, MRL	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Richard R. Deluca	officer: EVP&Pres, Merck Animal Heallth	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell	officer: EVP,Human Resources	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Rita A Karachun	officer: Sr. VP Fince-Global Controller	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary	officer: EVP, General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay	officer: Exe V-P & Pres. MMD	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier	officer: Chairman, President & CEO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033